Five years ago, XenoPort (NASDAQ:XNPT) was a $40 stock, but while the biotech sector has enjoyed a strong run these shares have gone the other way on disappointments over the restless leg drug Horizant and the clinical failures of arbaclofen placarbil. Although I don't see a credible path back to $40 anytime soon, the company's monomethyl fumarate (MMF) prodrug XPS23829 ('829) does give the company at least a fighting chance of grabbing some of the billions of dollars in revenue expected for Biogen Idec's (NASDAQ:BIIB) latest blockbuster Tecfidera. While the prospect of capturing some of Tecfidera's potential sales through competitive pricing or clinical differentiation is intriguing, investors shouldn't kid themselves about the risks and uncertainties...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|